Abstract:Using diverse arylmethyl groups to replace the benzyl moiety of the lead Hsp90 inhibitor 1 (N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-benzyl-1,2,3,4-tetrahydro-3-iso quinolinecarboxamide), thirty four derivatives (10-43) were developed, and exhibited improved Hsp90 inhibitory and antiproliferative activities. SAR analysis indicated that the southeastern aryl substitutions influenced their antiproliferative activities obviously, with the para-pyridyl group (41) outperforming all other substitution patterns. In this regard, compound 41 was selected for further evaluation. CETSA melt and ITDRFCETSA (isothermal dose-response fingerprint) curves for Hsp90α further proved that 41 interacted with intracellular Hsp90α powerfully. Compared with the lead compound 1, docking and MD refinement of the Hsp90α-41 complex revealed a favorable H-bonding interaction between the side-chain of Tyr139 and the pyridine moiety of 41, which is the first time to be used for resorcinol-based Hsp90 inhibitors. With broad-spectral antitumor activity, compound 41 induced time- and dose-dependent growth inhibition and G0/G1 cell cycle arrest on human breast cancer MDA-MB-453 cell line. In addition, flow cytometry and Western blot analyses confirmed that 41 induced apoptosis of human breast cancer MDA-MB-453 cell line. Via degradation of IKKs and suppression of IKKs activity, compound 41 inhibited TNF-α-induced NF-κB activation. The overall properties warrant compound 41 a promising Hsp90 inhibitor and further biological characterizations. This study provides insights into the chemical evolution of Hsp90 inhibitors, and may facilitate the design of next generation Hsp90 inhibitors for the antitumor drug development.

Design, Synthesis and Biological Evaluation of 17-Arylmethylamine-17-demethoxygeldanamycin Derivatives As Potent Hsp90 Inhibitors

Synthesis and Preliminary Antitumor Activity Evaluation of 17-(5-(substituted Cinnamamido)pentylamino)-17-demethoxygeldanamycin Derivatives As Potent Hsp90 Inhibitors

In Vitro and in Vivo Evaluation of 17-Phenylpropylamine/phenoxyethylamine-17-demethoxygeldanamycins As Potent Hsp90 Inhibitors

Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.

Discovery of Diamine-Linked 17-Aroylamido-17-demethoxygeldanamycins As Potent Hsp90 Inhibitors

Synthesis of Novel 17-[3,6-dioxa-8-n-(substituted Cinnamyol)-Octanediamino]-17-demethoxygeldanamycin Derivatives

17-DMCHAG, a New Geldanamycin Derivative, Inhibits Prostate Cancer Cells Through Hsp90 Inhibition and Survivin Downregulation

SNX-25a, a Novel Hsp90 Inhibitor, Inhibited Human Cancer Growth More Potently Than 17-AAG.

17-Abag, A Novel Geldanamycin Derivative, Inhibits Lncap-Cell Proliferation Through Heat Shock Protein 90 Inhibition

Design, Synthesis and Pharmacological Evaluation of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-arylmethyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamides As Potent Hsp90 Inhibitors.

Synthesis and Biological Evaluation of Novel Spin Labeled 18Β-Glycyrrhetinic Acid Derivatives

Potent Hsp90 Inhibitors with Significant Potential in Cancer Therapy

Design, Synthesis, and Biological Evaluation of Truncated Deguelin Derivatives As Hsp90 Inhibitors

Discovery of 18Β-Glycyrrhetinic Acid Conjugated Aminobenzothiazole Derivatives As Hsp90-Cdc37 Interaction Disruptors That Inhibit Cell Migration and Reverse Drug Resistance

Synthesis and evaluation of the antitumor activity of 2-amino-4-tetrahydroindazole-substituted benzamide derivatives as HSP90 inhibitors

Design, Preparation and Studies Regarding Cytotoxic Properties of Glycyrrhetinic Acid Derivatives.

Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells

Synthesis and Antiviral and Antitumor Activities of Novel 18β-Glycyrrhetinic Acid Derivatives

In Vivo and in Vitro Antitumor Activity of 17-Allylamino-17-demethoxygeldanamycin

Design, synthesis and biological evaluation of a new class of Hsp90 inhibitors vibsanin C derivatives

The HSP90 Inhibitor 17-PAG Effectively Inhibits the Proliferation and Migration of Androgen-Independent Prostate Cancer Cells